<DOC>
	<DOCNO>NCT00047489</DOCNO>
	<brief_summary>ABT-751 new antitumor drug interferes cell division . The goal clinical research study find high safe dose ABT-751 give treatment refractory hematologic malignancy . The safety side effect ABT-751 also study .</brief_summary>
	<brief_title>Study ABT-751 Patients With Refractory Hematologic Malignancies</brief_title>
	<detailed_description>The current low cure rate patient advance hematologic cancer indicate need identify new agent incorporate current therapy improve prognosis . The vinca alkaloid effective broad-spectrum anti-leukemic drug . Microtubules major structural component cell . They play role cell shape , cellular polarity , cellular movement , intracellular transport segregation chromosome mitosis . The cellular microtubule dynamic highly regulate . As cell enter mitosis , interphase microtubule disappear replace new network microtubule interact mitotic spindle . Disruption new microtubule lead cell cycle arrest . These important highly labile microtubule array comprise mitotic spindle principal target oncologic antimitotic compound . Known antimitotic agent fall three class , vinca alkaloid ( vincristine , vinblastine , vinorelbine ) , taxanes ( paclitaxel docetaxel ) , colchicine-site binder . There colchicine-site agent currently approve cancer chemotherapy . These three class compound distinct bind site tubulin subunit . ABT-751 novel orally administer antimitotic agent bind colchicine site beta-tubulin inhibits polymerization microtubule .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Patients relapse refractory acute leukemia ( AML , ALL , MDS [ RAEB , RAEBT ] , CMML transformation &gt; /= 10 % peripheral blood/bone marrow blast , CML blast crisis ) , patient relapsed/refractory transform CLL . Signed informed consent indicate patient aware investigational nature study , keep policy hospital . ECOG performance status &lt; /= 2 . Serum direct bilirubin &lt; /= 2 mg/dL , serum SGOT SGPT &lt; 3 upper limit normal , serum creatinine &lt; /= 2 mg/dL , unless consider due organ leukemic involvement . Age &gt; 16 year separate Phase I study conduct pediatric population . Exclusion Criteria Any severe , concurrent disease , infection , comorbidity , judgment Investigator , would make patient inappropriate study entry . Pregnant and/or lactate female . Those documented sulfonamide allergy exclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>